NCT02666001 is a Phase 1 clinical trial of BMS-663068 in Infection, Human Immunodeficiency Virus, sponsored by ViiV Healthcare.

Who is sponsoring NCT02666001?

NCT02666001 is sponsored by ViiV Healthcare.

What drugs are being tested in NCT02666001?

Interventions in NCT02666001: BMS-663068, Methadone, Buprenorphine and Norbuprenorphine.

What condition does NCT02666001 study?

NCT02666001 studies Infection, Human Immunodeficiency Virus.

Is NCT02666001 still recruiting?

NCT02666001 is currently completed. Last updated 9 August 2017.

Last reviewed 2017-08-09 · How we verify

NCT02666001

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Assess the Drug-drug Interaction of BMS 663068 With Methadone and Also With Buprenorphine/Naloxone

Completed Phase 1 Last updated 9 August 2017

What this trial tests

Phase 1 trial testing BMS-663068 in Infection, Human Immunodeficiency Virus in 32 participants. Completed in 29 June 2016.

Timeline

12 January 2016

Primary endpoint
29 June 2016

29 June 2016

Quick facts

Lead sponsor	ViiV Healthcare
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	crossover
Masking	none
Primary purpose	other
Enrollment	32
Start date	12 January 2016
Primary completion	29 June 2016
Estimated completion	29 June 2016
Sites	2 locations across United States

Drugs / interventions tested

BMS-663068 — full drug profile →
Methadone (METHADONE) — full drug profile →
Buprenorphine and Norbuprenorphine — full drug profile →

Conditions studied

Infection, Human Immunodeficiency Virus — all drugs for Infection, Human Immunodeficiency Virus →

Sponsor

ViiV Healthcare — full company profile →

Who can join

Adults 18 to 65, any sex, with Infection, Human Immunodeficiency Virus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study is being conducted to assess the effect of multiple doses of BMS-663068 on the exposure of methadone in subjects on a stable dose of methadone, and the exposure of buprenorphine and norbuprenorphine in subjects on a stable dose of buprenorphine and norbuprenorphine.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Methadone and buprenorphine pharmacokinetics and pharmacodynamics when coadministered with fostemsavir to opioid-dependent, human immunodeficiency virus seronegative participants.
Moore K, Magee M, Sevinsky H, Chang M, et al · · 2019 · cited 9× · PMID 30980734 · DOI 10.1111/bcp.13964

Verify or expand the search:

Other trials of BMS-663068

Trials testing the same drug.

NCT02805556 — Absolute Bioavailability of BMS-626529 After Oral and Intravenous Dosing · Phase 1 · completed
NCT02666053 — A Study to Assess the Effect of High Fat Meal and Increased Gastric pH on the Bioavailability of an Extended Release For · Phase 1 · completed
NCT02508064 — Bioavailability of BMS-626529 in Healthy Subjects From Prototype Low Dose Extended Release Formulations (Part 1) and Pro · Phase 1 · completed
NCT02480894 — A Open-label, Drug-Drug Interaction With Maraviroc (DDI) · Phase 1 · completed
NCT02480881 — A Drug-drug Interaction Study Between BMS-663068 and Oral Contraceptives in Healthy Female Volunteers (DDI) · Phase 1 · completed

Other recruiting trials for Infection, Human Immunodeficiency Virus

Currently open trials in the same condition.

NCT02951052 — Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpiv · Phase 3 · active not recruiting

Other ViiV Healthcare trials

Trials by the same sponsor.

NCT07393659 — A Continued Access Study for Participants Transitioning From ViiV Healthcare-sponsored or ViiV Healthcare-collaborative · Phase 3 · not yet recruiting
NCT07525544 — A Study to Investigate the Safety and PK of VH4770359 in Healthy Participants · Phase 1 · not yet recruiting
NCT07275606 — A Study to Investigate Cabotegravir for Neonates Exposed to HIV-1 · Phase 1, PHASE2 · not yet recruiting
NCT07202546 — A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study) · Phase 2 · recruiting
NCT07053384 — A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Vir · Phase 1 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02666001 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by ViiV Healthcare
Last refreshed: 9 August 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02666001.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing